Monday, September 26, 2022 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

PHOENIX - Insys Therapeutics goosed its share price with false and deceptive statements and unethical ads about its Subsys drug, and the price dropped by 17% in a day when the truth came out, shareholders claim in a federal class action.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...